WELL-STUDIED
SAFETY
PROFILE

Approved for ages 2+ for pJIA and JPsA. *JPsA=juvenile psoriatic arthritis pediatric patients aged 2 to less than 18 years.

Approved in 8 Indications1-3

12 YEARS
of clinical trial experience2*

26 CLINICAL TRIALS ACROSS 8
INDICATIONS: RA, PsA, AS, nr-axSpA, AD, UC, CD & pJIA1,3

>15,000
patients in global clinical trials across US‑approved indications, including 2+ years in pJIA and pediatrics 12+ years in AD1,3

~6 YEARS
of real-world experience1

OVER 375,000
patients prescribed globally across indications since 20191,4†

>45,000
patient-years of exposure to RINVOQ (15, 30, 45 mg) or RINVOQ LQ (1 mg/mL)3

*Clinical experience encompasses the time from first RINVOQ patient dosed in RA clinical trial to present.

Based on prescription data with RINVOQ in patients with RA, PsA, nr-axSpA, AS, AD, UC, or CD as of June 2024.4

AD=atopic dermatitis; AS=ankylosing spondylitis; CD=Crohn’s disease; IR=intolerance or inadequate response; nr-axSpA=non-radiographic axial spondyloarthritis; pJIA=polyarticular juvenile idiopathic arthritis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis.

Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.

Learn more about RINVOQ safety in specific conditions

Visit the disease state of interest for details

Safety Profile in

RHEUMATOLOGY

Safety Profile in

DERMATOLOGY

Safety Profile in

GASTROENTEROLOGY

Safety Considerations

Consider the Benefits and Risks for the Individual Patient Prior to Initiating Therapy with RINVOQ